This course is part of the Managing Agitation in Alzheimer’s Dementia: Current and Future Approaches curriculum.
Doctor talking to patient

This course is part of the Managing Agitation in Alzheimer’s Dementia: Current and Future Approaches curriculum.

Interactive Learning

0.50 CME Credit

New and Emerging Therapies for Agitation Associated with Dementia Due to Alzheimer’s Disease (AD)An Interactive Learning Experience
This course is hosted by an external partner. By clicking Begin, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

Agitation is among the most common behavioral symptoms in patients with dementia, including Alzheimer’s dementia. It exacts a significant burden on patients because it is associated with not only greater morbidity and mortality, but also a faster cognitive and functional decline. This activity reviews pharmacological treatment options, both a newly approved agent that is the first ever to be indicated specifically for the treatment of agitation associated with dementia due to Alzheimer’s disease and also an array of agents in development.

Begin

CME Information

0.50 AMA PRA Category 1 Credits™, 0.50 ABIM MOC or 0.36 AANP, including 0.36 AANP Pharm

Release Date: 7/14/2023

Expiration Date: 7/14/2024

Topics

Faculty

Learning Objectives

  • Review efficacy and safety data for the first therapy approved for agitation associated with dementia due to Alzheimer’s disease
  • Discuss the mechanism of action and available efficacy and safety data for emerging therapies for agitation associated with dementia due to Alzheimer’s disease

State Licensure Requirements

This activity may satisfy topic-based CME/CE requirements on Geriatric Medicine, Alzheimer’s Disease and Dementia. Please check with your state licensing board for their specific requirements and print this page as documentation, as might be needed.

This session is designed to satisfy CME/CE requirements in the following states:
CA: Geriatrics (MD/DO)
CT: Alzheimer’s/Dementia (NP)
IL: Alzheimer’s/Dementia (MD/PA/NP)
MA: Alzheimer’s/Dementia (MD/DO)
NV: Geriatrics (NP)
RI: Alzheimer’s/Dementia (MD/DO/NP)
TX: Geriatrics (NP)

Faculty

Pierre N. Tariot, MD

Director
Banner Alzheimer’s Institute
Co-Director
Alzheimer’s Prevention Initiative
Research Professor of Psychiatry
University of Arizona College of Medicine
Phoenix, Arizona

Learn More

Disclosures

The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.

Pierre N. Tariot, MD: Advisor for AC Immune, Acadia, Athira, Corium Cortexyme, Eisai, Genentech, Merck, Novo Nordisk, Otsuka Lundbeck; Consultant for Abbvie, Acadia, Otsuka & Astex, T3D Therapeutics; Researcher for Abbvie, Biogen, Cortexyme, Eli Lilly, Genentech, Merck, NIA, Novartis, Roche; Royalties or Patent Beneficiaries for U.S. Patent # 11/632,747.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME Information

AMA PRA Category 1 Credits™

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of Pri-Med Institute and Miller Medical Communications. Pri-Med Institute is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This activity is approved for 0.36 contact hours of continuing education, which includes 0.36 hours of pharmacology.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 2 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

Commercial Supporter

Otsuka America Pharmaceutical, Inc. and Lundbeck

Education Partner

Miller Medical Communications, LLC

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

New and Emerging Therapies for Agitation Associated with Dementia Due to Alzheimer’s Disease (AD)

Begin